7 results
This study aims to investigate the effect of switching from Atripla® to Eviplera® on neurocognitive performances (neurocognitive testing) and imaging (functional MRI scanning) in virologically suppressed HIV-infected patients and stable on atripla.
The aim of this randomized controlled trial is to determine the affect of screening on the Gastrointestinal symptoms (GIS) and Health Related Quality of Life (HRQL) in asymptomatic first degree relatives of CD patients. On the basis of the results,…
Our primary objective is to investigate the effects of endotoxin-induced systemic inflammation and subsequent development of endotoxin tolerance on the inflammatory response following Fluenz® administration in vivo. To evaluate whether these effects…
This study has been transitioned to CTIS with ID 2024-516631-27-00 check the CTIS register for the current data. The evaluation of R-IrAE's after ICI therapy, specifically incidence, treament of R-IrAE's, response to said treatment,…
The main objective is to evaluate whether adalimumab dose reduction using adalimumab serum measurements (TDM strategy) will minimize medical costs, compared to disease activity guided dose reduction in rheumatoid arthritis (RA) patients.
2.1 Primary ObjectiveDescribing the association between Handscan optical scores, markers of inflammation (levels of CRP, serum IL-6) and clinical swollen joint score in three treatment groups with different pharmacokinetic modes of action for RA…
This study aims to investigate the effect of switching from Atripla® to Eviplera® on neurocognitive performances (neurocognitive testing) and imaging (functional MRI scanning) in virologically suppressed HIV-infected patients and stable on atripla.